NASACORT HFA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Nasacort Hfa, and when can generic versions of Nasacort Hfa launch?
Nasacort Hfa is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in NASACORT HFA is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Sixty-nine suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Nasacort Hfa
A generic version of NASACORT HFA was approved as triamcinolone acetonide by TARO on October 1st, 1986.
Summary for NASACORT HFA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 82 |
| Clinical Trials: | 8 |
| Patent Applications: | 4,302 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | NASACORT HFA at DailyMed |
Recent Clinical Trials for NASACORT HFA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Gail Gauvreau | N/A |
| Stanford University | Phase 4 |
| Sanofi | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for NASACORT HFA
US Patents and Regulatory Information for NASACORT HFA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | NASACORT HFA | triamcinolone acetonide | SPRAY, METERED;NASAL | 020784-001 | Apr 7, 2004 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
